Cerebrospinal fluid biomarkers predict clinical evolution in patients with subjective cognitive decline and mild cognitive impairment

Neurodegenerative Diseases

Volumn 16, Issue 1-2, 2016, Pages 69-76

  Sierra Rio, Alba ^a   Balasa, Mircea ^b,c   Olives, Jaume ^b   Antonell, Anna ^b,c   Iranzo, Alex ^c   Castellví, Magda ^b   Bosch, Beatriz ^b,c   Grau Rivera, Oriol ^b   Fernandez Villullas, Guadalupe ^b   Rami, Lorena ^b,c   Lladó, Albert ^b,c   Sánchez Valle, Raquel ^b,c   Molinuevo, José Luis ^b,c  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

Alzheimer's disease; Biomarkers; Cerebrospinal fluid; Mild cognitive impairment; Subjective cognitive decline

Indexed keywords

APOLIPOPROTEIN E4; RESTRICTION ENDONUCLEASE; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); APOLIPOPROTEIN E; BIOLOGICAL MARKER; MAPT PROTEIN, HUMAN; PEPTIDE FRAGMENT; TAU PROTEIN;

ADULT; ALLELE; ALZHEIMER DISEASE; BRAIN FUNCTION; CEREBROSPINAL FLUID; CLINICAL EVALUATION; COGNITIVE DEFECT; CONFERENCE PAPER; DEMOGRAPHY; DIFFUSE LEWY BODY DISEASE; DISEASE COURSE; FEMALE; FOLLOW UP; FRONTOTEMPORAL DEMENTIA; GENOTYPE; HIPPOCAMPAL SCLEROSIS; HUMAN; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; PARASOMNIA; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE; AGED; GENETICS; KAPLAN MEIER METHOD; NEUROPSYCHOLOGICAL TEST; REGRESSION ANALYSIS;

AGED; AMYLOID BETA-PEPTIDES; APOLIPOPROTEINS E; BIOMARKERS; COGNITION DISORDERS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; NEUROPSYCHOLOGICAL TESTS; PEPTIDE FRAGMENTS; PROGNOSIS; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; RISK FACTORS; TAU PROTEINS;

EID: 84958039470     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000439258     Document Type: Conference Paper

References (33)

1. Reitz C, Brayne C, Mayeux R: Epidemiology of Alzheimer disease. Nat Rev Neurol 2011; 7: 137-152.
2. Braak H, Braak E: Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239-259.
3. Beach TG, Monsell SE, Phillips LE, Kukull W: Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. J Neuropathol Exp Neurol 2012; 71: 266-273.
4. Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P, Dean R, Siemers E, Potter W, Lee VM, Trojanowski JQ; Alzheimer's Disease Neuroimaging Initiative: Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009; 65: 403-413.
5. Schoonenboom NS, Reesink FE, Verwey NA, Kester MI, Teunissen CE, van de Ven PM, Pijnenburg YA, Blankenstein MA, Rozemuller AJ, Scheltens P, van der Flier WM: Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Neurology 2012; 78: 47-54.
6. Welge V, Fiege O, Lewczuk P, Mollenhauer B, Esselmann H, Klafki HW, Wolf S, Trenkwalder C, Otto M, Kornhuber J, Wiltfang J, Bibl M: Combined CSF tau, p-tau181 and amyloid- beta38/40/42 for diagnosing Alzheimer's disease. J Neural Transm 2009; 116: 203-212.
7. Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, DeKosky ST, Gauthier S, Selkoe D, Bateman R, Cappa S, Crutch S, Engelborghs S, Frisoni GB, Fox NC, Galasko D, Habert MO, et al: Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol 2014; 13: 614-629.
8. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, Ritchie K, Rossor M, Thal L, Winblad B: Current concepts in mild cognitive impairment. Arch Neurol 2001; 58: 1985-1992.
9. Reisberg B, Shulman MB, Torossian C, Leng L, Zhu W: Outcome over seven years of healthy adults with and without subjective cognitive impairment. Alzheimers Dement 2010; 6: 11-24.
10. Jessen F, Amariglio RE, van Boxtel M, Breteler M, Ceccaldi M, Chetelat G, Dubois B, Dufouil C, Ellis KA, van der Flier WM, Glodzik L, van Harten AC, de Leon MJ, McHugh P, et al: A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimers Dement 2014; 10: 844-852.
11. Jicha GA, Parisi JE, Dickson DW, Johnson K, Cha R, Ivnik RJ, Tangalos EG, Boeve BF, Knopman DS, Braak H, Petersen RC: Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol 2006; 63: 674-681.
12. Price JL, Morris JC: Tangles and plaques in nondemented aging and 'pre-clinical' Alzheimer's disease. Ann Neurol 1999; 45: 358-368.
13. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L: Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006; 5: 228-234.
14. Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM: Cerebrospinal fluid tau/beta-amyloid42 ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 2007; 64: 343-349.
15. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, et al: CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009; 302: 385-393.
16. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH: The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 263-269.
17. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, et al: Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005; 65: 1863-1872.
18. Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, van Swieten JC, Seelaar H, Dopper EG, Onyike CU, Hillis AE, Josephs KA, Boeve BF, Kertesz A, Seeley WW, et al: Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain 2011; 134: 2456-2477.
19. Del Campo M, Mollenhauer B, Bertolotto A, Engelborghs S, Hampel H, Simonsen AH, Kapaki E, Kruse N, Le Bastard N, Lehmann S, Molinuevo JL, Parnetti L, Perret-Liaudet A, Saez-Valero J, et al: Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. Biomark Med 2012; 6: 419-430.
20. Antonell A, Fortea J, Rami L, Bosch B, Balasa M, Sanchez-Valle R, Iranzo A, Molinuevo JL, Llado A: Different profiles of Alzheimer's disease cerebrospinal fluid biomarkers in controls and subjects with subjective memory complaints. J Neural Transm 2011; 118: 259-262.
21. Molinuevo JL, Gispert JD, Pujol J, Rojas S, Llado A, Balasa M, Antonell A, Sanchez-Valle R, Rami L: A new approach to the Alzheimer's disease diagnosis with biomarkers: description of the AD-CSF-Index. Rev Neurol 2012; 54: 513-522.
22. Iranzo A, Tolosa E, Gelpi E, Molinuevo JL, Valldeoriola F, Serradell M, Sanchez-Valle R, Vilaseca I, Lomena F, Vilas D, Llado A, Gaig C, Santamaria J: Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study. Lancet Neurol 2013; 12: 443-453.
23. Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O: Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5-10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 2012; 69: 98-106.
24. Parnetti L, Chiasserini D, Eusebi P, Giannandrea D, Bellomo G, De Carlo C, Padiglioni C, Mastrocola S, Lisetti V, Calabresi P: Performance of Aβ 1-40 , Aβ 1-42 , total tau, and phosphorylated tau as predictors of dementia in a cohort of patients with mild cognitive impairment. J Alzheimers Dis 2012; 29: 229-238.
25. Balasa M, Sanchez-Valle R, Antonell A, Bosch B, Olives J, Rami L, Castellvi M, Molinuevo JL, Llado A: Usefulness of biomarkers in the diagnosis and prognosis of early-onset cognitive impairment. J Alzheimers Dis 2014; 40: 919-927.
26. Schneider JA, Arvanitakis Z, Bang W, Bennett DA: Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 2007; 69: 2197-2204.
27. Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C: Age, neuropathology, and dementia. N Engl J Med 2009; 360: 2302-2309.
28. Vos S, van Rossum I, Burns L, Knol D, Scheltens P, Soininen H, Wahlund LO, Hampel H, Tsolaki M, Minthon L, Handels R, L'Italien G, van der Flier W, Aalten P, Teunissen C, et al: Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI. Neurobiol Aging 2012; 33: 2272-2281.
29. Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ: Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010; 9: 119-128.
30. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr, Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, et al: Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 280-292.
31. Visser PJ, Verhey F, Knol DL, Scheltens P, Wahlund LO, Freund-Levi Y, Tsolaki M, Minthon L, Wallin AK, Hampel H, Burger K, Pirttila T, Soininen H, Rikkert MO, Verbeek MM, Spiru L, Blennow K: Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol 2009; 8: 619-627.
32. Saykin AJ, Wishart HA, Rabin LA, Santulli RB, Flashman LA, West JD, McHugh TL, Mamourian AC: Older adults with cognitive complaints show brain atrophy similar to that of amnestic MCI. Neurology 2006; 67: 834-842.
33. Perrotin A, Mormino EC, Madison CM, Hayenga AO, Jagust WJ: Subjective cognition and amyloid deposition imaging: a Pittsburgh Compound B positron emission tomography study in normal elderly individuals. Arch Neurol 2012; 69: 223-229.